Literature DB >> 15701577

The use of unlicensed and off-label medicines in the neonate.

Sharon Conroy1, John McIntyre.   

Abstract

The use of unlicensed and off-label medicines in neonates in intensive care is common and widespread. Up to 93% of babies receive at least one unlicensed or off-label medicine during their stay in intensive care. Such practice is an essential part of their care and should be done based on the best evidence available. However, problems arise - on an every-day basis - because of the lack of appropriate information and licensed medicine formulations for neonates. These problems include the selection of appropriate medicine and dose, administration and the increased risk of medication errors. Initiatives to improve the situation are underway in the US and are proposed in Europe. However, more urgent action is required to stop these babies continuing to be deprived of their basic human rights to safe, effective and high-quality therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701577     DOI: 10.1016/j.siny.2004.11.003

Source DB:  PubMed          Journal:  Semin Fetal Neonatal Med        ISSN: 1744-165X            Impact factor:   3.926


  29 in total

1.  Perceptions and attitudes of Jordanian paediatricians towards off-label paediatric prescribing.

Authors:  Tareq L Mukattash; Mayyada Wazaify; Najwa Khuri-Boulos; Anan Jarab; Ahmed F Hawwa; James C McElnay
Journal:  Int J Clin Pharm       Date:  2011-09-28

Review 2.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

Review 3.  Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future.

Authors:  Kate O'Hara; Ian M R Wright; Jennifer J Schneider; Alison L Jones; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2015-10-26       Impact factor: 4.335

4.  The launch of the British National Formulary for Children.

Authors:  A Elias-Jones; G Rylance
Journal:  Arch Dis Child       Date:  2005-10       Impact factor: 3.791

Review 5.  Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature.

Authors:  Indra Chedoe; Harry A Molendijk; Suzanne T A M Dittrich; Frank G A Jansman; Johannes W Harting; Jacobus R B J Brouwers; Katja Taxis
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  How well are general practice trainees prepared for paediatric prescribing?

Authors:  N M Isa; Michael W Taylor; Peter J Helms; James S McLay
Journal:  Br J Clin Pharmacol       Date:  2008-11-24       Impact factor: 4.335

7.  Drug treatments in a neonatal setting: focus on the off-label use in the first month of life.

Authors:  Angelica Dessì; Claudia Salemi; Vassilios Fanos; Laura Cuzzolin
Journal:  Pharm World Sci       Date:  2010-02-07

Review 8.  How to optimize the evaluation and use of antibiotics in neonates.

Authors:  Evelyne Jacqz-Aigrain; Florentia Kaguelidou; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-09-01       Impact factor: 3.278

9.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

10.  Documentation of pediatric drug safety in manufacturers' product monographs: a cross-sectional evaluation of the canadian compendium of pharmaceuticals and specialities.

Authors:  Navjeet K Uppal; Lee L Dupuis; Christopher S Parshuram
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.